AR and prostate carcinoma: Melatonin treatment in LNCaP prostate cancer cells inhibited IL-6 upregulation and suppressed the NFκB-mediated upregulation of AR-V7 demonstrating how the indolamine can impede AR-V7-mediated carcinogenesis and downregulate the receptor variant entirely.